Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Noveris Health Sciences Inc. is a publicly traded health sciences company listed on the U.S. OTC Markets under the ticker MYCOF. Based on publicly available filings and market disclosures, the company is focused on drug development and therapeutic research within the biopharmaceutical and mental health sectors, with an emphasis on novel treatment modalities. The company’s activities are concentrated in early-stage research and development rather than commercial-scale product sales, and it has historically generated limited operating revenue.
The company traces its origins to Mydecine Innovations Group Inc., which was founded in 2020 and pursued research into psychedelic-assisted therapies and novel drug delivery technologies. Public disclosures indicate that the company later undertook a corporate rebranding and restructuring, resulting in the Noveris Health Sciences Inc. name. Available sources confirm that the company’s evolution has included shifts in strategic focus, leadership, and asset composition. Certain aspects of the transition and current operational scale remain unclear due to limited recent filings and sparse financial disclosures.
Business Operations
Noveris Health Sciences Inc. operates primarily through research and development activities related to therapeutic compounds and health science innovations. Historically, its core business lines included drug discovery, intellectual property development, and clinical-stage research programs targeting mental health conditions and substance use disorders. Revenue generation has largely depended on capital markets financing rather than recurring commercial sales, as no products have been confirmed as fully commercialized.
The company’s operations are primarily domestic, with research activities historically tied to North America. Public records reference the use of proprietary research platforms and preclinical development assets, though details on active laboratories, owned facilities, or manufacturing capabilities are limited. Information regarding current subsidiaries, joint ventures, or active commercial partnerships is inconsistent across sources; therefore, the full scope of operating entities cannot be conclusively verified based on available public data.
Strategic Position & Investments
Strategically, Noveris Health Sciences Inc. has positioned itself as an early-stage innovator in emerging therapeutic categories, historically including psychedelic-derived compounds and next-generation mental health treatments. Growth initiatives disclosed in prior investor materials emphasized advancing compounds through preclinical and clinical milestones, expanding intellectual property portfolios, and seeking strategic collaborations to offset development risk.
The company has previously announced investments in research programs and the acquisition or development of proprietary drug candidates under the former Mydecine Innovations Group Inc. structure. However, recent public disclosures provide limited confirmation of ongoing acquisitions, active portfolio companies, or late-stage clinical assets under the Noveris Health Sciences Inc. name. As a result, the current strategic investment posture and pipeline maturity are not fully verifiable from publicly available sources.
Geographic Footprint
Noveris Health Sciences Inc. is headquartered in North America, with historical corporate offices and management functions based in Canada and market access in the United States through its OTC listing. The company’s operational footprint has been relatively limited, reflecting its development-stage status and small organizational scale.
While earlier disclosures referenced research collaborations and intellectual property considerations with potential international relevance, there is no clear evidence of significant operational facilities, manufacturing sites, or revenue-generating subsidiaries outside North America. International influence appears to be primarily indirect, through capital markets exposure and intellectual property filings rather than physical operations.
Leadership & Governance
Leadership information for Noveris Health Sciences Inc. is derived from historical disclosures and regulatory filings, some of which predate the company’s rebranding. Governance has been overseen by a board of directors and executive team with backgrounds in biotechnology, capital markets, and early-stage drug development. The leadership philosophy communicated in prior filings emphasized innovation, disciplined capital allocation, and advancing differentiated therapeutic platforms.
Key executives and directors publicly associated with the company in recent and historical disclosures include:
- Joshua Bartch – Former Chief Executive Officer
- Damon Michaels – Former Chairman of the Board
- Robert Roscow – Chief Financial Officer
- Rachael Hennessey – Former President
Publicly available sources do not consistently confirm the current executive roster following the transition to Noveris Health Sciences Inc.; therefore, certain leadership details are inconclusive based on available public sources.